Important information

Purchasing this item involves supplying 3 x Wegovy 2.4 mg pens. If your treatment request is approved, the weekly dose dispensed will be 7.2 mg, administered as three separate 2.4 mg injections on the same day, rather than a single 2.4 mg weekly dose.

What is Wegovy

Wegovy PF Pen is a pre-filled injection pen containing Semaglutide, manufactured by Novo Nordisk. It is designed to support significant and sustainable weight loss. Semaglutide works by interacting with your brain to help you feel fuller for longer and reduce cravings. When combined with a calorie-controlled diet and increased exercise, Wegovy has been shown to enhance weight loss more than diet and exercise alone.

Who is Wegovy for

Wegovy PF Pen is intended for adults aged 18 to 75 who meet specific criteria:

1. Previous weight management attempts
   Individuals who have not achieved sufficient weight loss through supervised diet, behaviour changes, and increased physical activity.
2. Body Mass Index (BMI) requirements *
   • BMI of 30 kg/m² or higher or
   • BMI of 27 kg/m² or higher with at least one weight-related health condition, such as:
     • High blood pressure (hypertension)
     • High cholesterol levels (dyslipidaemia)
     • Obstructive sleep apnoea (a sleep disorder)
     • Type 2 diabetes

Dosage

Wegovy uses a gradual, step-by-step dosing schedule to help your body adjust and minimize potential side effects as you progress to a higher, effective dose. You’ll start at a low dose and gradually increase it every four weeks until reaching your maintenance level.

Please select the Wegovy dose recommended in your personal treatment plan, starting with the 0.25 mg dose (this product). If you're unsure about the appropriate dosage, please consult our pharmacist (pharmacy@medino.com) before placing your order.

For individuals with a BMI over 50, we advise consulting with a doctor or specialist for a comprehensive treatment plan.

Patient information leaflet

Our service does not include a prescription. Instead, your treatment will be supplied under a legal framework called Patient Group Direction (PGD), and the process will follow these steps:

1. Complete a health questionnaire:

Provide detailed information about your health, medical history, and previous weight management attempts.

2. Pharmacist assessment:

Our pharmacist will review your responses and may reach out via phone or video call to confirm your suitability for Mounjaro.

3. Private consultation:

All consultations are private and confidential. This gives you the opportunity to ask questions and ensure Mounjaro is the right choice for your needs.

4. All-inclusive pricing:

The price you pay includes the consultation fee, with no hidden costs.

5. Identity verification:

You'll need to provide identification during the consultation to confirm that you are the intended user. This is required only during your first order.

6. Photographic evidence request:

You’ll be asked to submit photographic evidence of your weight, height, and relevant medical history to ensure safe and accurate consultation.

Purchasing this medication does not guarantee its supply. The decision if this medication is right for you will be made together with the pharmacist during your consultation, and ultimately the decision to supply the medication is with the pharmacist. Any orders found not suitable will be refunded.

Each dose contains 2.4mg of semaglutide in 0.75mL solution.

One pre-filled pen contains 9.6 mg (four doses) of semaglutide in 3 mL solution.

Other ingredients: Disodium phosphate, dihydrate Propylene glycol, Phenol, Hydrochloric acid (for pH adjustment), Sodium hydroxide (for pH adjustment), Water for injection.

12 needles are included in the box.

Inject 2.4mg subcutaneously three times to reach 7.2mg, once per week for 4 weeks (28 days), leaving 5cm between injection sites and rotating area each week.

Wegovy FlexTouch pen is designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm - these are included in the box.

The day of weekly administration can be changed if necessary, as long as the time between two doses is at least 3 days (>72 hours). After selecting a new dosing day, once-weekly dosing should be continued.

Wegovy is for subcutaneous use only and should not be administered intravenously or intramuscularly.

It should be injected in the abdomen, thigh or upper arm. The injection site and timing can be changed without dose adjustment.

Wegovy should not be mixed with other medicinal products.

Gastrointestinal Effects:

Sometimes, this medicine might cause stomach issues. This can lead to dehydration in rare cases, which can affect your kidneys. If you notice any stomach problems, be aware of the risk of dehydration and make sure to drink enough water.

Acute Pancreatitis:

In rare cases, our medication can cause a problem with your pancreas called acute pancreatitis. It's essential to know the symptoms of this issue. If you ever suspect you have it, stop taking the medication and talk to your doctor. If it's confirmed, don't restart the medication. Be cautious if you've had pancreatitis before.

For Patients with Diabetes:

If you have diabetes, remember that this medication isn't a replacement for insulin.

Hypoglycemia in Patients with Diabetes:

If you have diabetes and you're taking this medication along with insulin or certain other diabetes drugs, you might be at a higher risk of low blood sugar (hypoglycemia). To reduce this risk, your doctor might adjust your insulin or other medications. We haven't studied adding this medication if you're already taking insulin.

Diabetic Retinopathy in Patients with Type 2 Diabetes:

If you have type 2 diabetes and you're using this medication, you should be aware that there's a slightly higher risk of complications with your eyes. Rapid improvement in your blood sugar control can sometimes temporarily worsen diabetic retinopathy. Make sure to keep a close eye on your eye health and follow your doctor's advice.

Populations Not Studied:

We don't have enough information about how this medication affects people with severe heart problems (New York Heart Association class IV) or people who are 75 years or older.

Sodium Content:

The medication has very little sodium, so you don't need to worry about your salt intake when using it.

Pregnancy and breastfeeding

This product should not be used during pregnancy and breastfeeding.

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Serious side effects

Common: may affect up to 1 in 10 people

• Complications of diabetic eye disease (diabetic retinopathy). If you have diabetes, you should inform your doctor if you experience eye problems, such as changes in vision, during treatment with this medicine.

Uncommon: may affect up to 1 in 100 people

• Inflamed pancreas (acute pancreatitis). Signs may include severe and long-lasting pain in your stomach, which may move to your back. Seek medical advice immediately if these symptoms occur.
• Kidney or bladder stones. Symptoms may include back or lower abdominal pain, difficulty urinating, or changes in urine colour.

Rare: may affect up to 1 in 1,000 people

• Severe allergic reactions (anaphylaxis, angioedema). Symptoms include breathing difficulties, swelling of the face, lips, tongue, or throat, difficulty swallowing, wheezing, rapid heartbeat, pale or cold skin, dizziness, or weakness. Urgent medical attention is required.
• Hip fractures.

Not known (frequency cannot be estimated from the available data)

• Bowel obstruction. A severe form of constipation that may be accompanied by abdominal pain, bloating, or vomiting.

Other side effects

Very common: may affect more than 1 in 10 people

• headache
• feeling sick (nausea)
• being sick (vomiting)
• diarrhoea
• constipation
• stomach pain
• feeling weak or tiredThese effects usually improve over time as the body adjusts.

Common: may affect up to 1 in 10 people

• feeling dizzy
• upset stomach or indigestion
• burping
• gas (flatulence)
• bloating
• inflamed stomach (gastritis), which may cause stomach pain, nausea, or vomiting
• reflux or heartburn (gastro-oesophageal reflux disease)
• gallstones
• hair loss
• injection site reactions
• change in the way food or drink tastes
• change in skin sensation, including dysaesthesia (abnormal or unpleasant nerve sensations such as burning, tingling, heightened skin sensitivity, or pain without an obvious cause)
• low blood sugar (hypoglycaemia) in patients with diabetes

Dysaesthesia has been reported more frequently at higher doses of semaglutide, including 7.2 mg, and appears to be dose-related. Patients should inform a healthcare professional if new or worsening sensory symptoms develop.

The warning signs of low blood sugar may appear suddenly and include cold sweats, cool or pale skin, headache, fast heartbeat, nausea, intense hunger, visual changes, drowsiness, weakness, anxiety, confusion, difficulty concentrating, or shaking.
Low blood sugar is more likely if this medicine is used alongside insulin or a sulfonylurea, and dose adjustments may be required.

Uncommon: may affect up to 1 in 100 people

• fast heartbeat
• increased pancreatic enzymes (such as lipase or amylase) seen on blood tests
• delayed stomach emptying
• low blood sugar (hypoglycaemia) in people without diabetes
• increased bilirubin levels in the blood